Remifentanil	remifentanil	O	O	OTHERS	I
pretreatment	pretreatment	O	O	O	O
reduces	reduces	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
after	after	O	O	O	O
etomidate	etomidate	O	O	OTHERS	I
.	.	O	O	O	O

STUDY	study	O	O	O	O
OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
aim	aim	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
compare	compare	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
pretreatment	pretreatment	O	O	O	O
with	with	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
1	1	O	O	O	O
microg/kg	microg/kg	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
gender	gender	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
after	after	O	O	O	O
anesthesia	anesthesia	O	O	O	O
induction	induction	O	O	O	O
with	with	O	O	O	O
etomidate	etomidate	O	O	OTHERS	I
.	.	O	O	O	O

DESIGN	design	O	O	O	O
:	:	O	O	O	O
This	this	O	O	O	O
was	was	O	O	O	O
a	a	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

SETTING	setting	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
conducted	conducted	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
university	university	O	O	O	O
hospital	hospital	O	O	O	O
.	.	O	O	O	O

PATIENTS	patients	O	O	O	O
:	:	O	O	O	O
Sixty	sixty	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
pretreated	pretreated	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
randomized	randomized	O	O	O	O
double-blinded	double-blinded	O	O	O	O
fashion	fashion	O	O	O	O
with	with	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
1	1	O	O	O	O
microg/kg	microg/kg	O	O	O	O
or	or	O	O	O	O
placebo	placebo	O	O	O	O
.	.	O	O	O	O

Two	two	O	O	O	O
minutes	minutes	O	O	O	O
after	after	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
or	or	O	O	O	O
placebo	placebo	O	O	O	O
injection	injection	O	O	O	O
,	,	O	O	O	O
etomidate	etomidate	O	O	OTHERS	I
0.3	0.3	O	O	O	O
mg/kg	mg/kg	O	O	O	O
was	was	O	O	O	O
given	given	O	O	O	O
.	.	O	O	O	O

MEASUREMENTS	measurements	O	O	O	O
:	:	O	O	O	O
Myoclonus	myoclonus	O	DISEASE	OTHERS	I
was	was	O	O	O	O
recorded	recorded	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
scale	scale	O	O	O	O
of	of	O	O	O	O
0	0	O	O	O	O
to	to	O	O	O	O
3	3	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
grade	grade	O	O	O	O
of	of	O	O	O	O
sedation	sedation	O	O	O	O
(	(	O	O	O	O
none	none	O	O	O	O
,	,	O	O	O	O
mild	mild	O	O	O	O
,	,	O	O	O	O
moderate	moderate	O	O	O	O
,	,	O	O	O	O
severe	severe	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
,	,	O	O	O	O
pruritus	pruritus	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
apnea	apnea	O	DISEASE	OTHERS	I
were	were	O	O	O	O
recorded	recorded	O	O	O	O
after	after	O	O	O	O
injection	injection	O	O	O	O
of	of	O	O	O	O
both	both	O	O	O	O
drugs	drugs	O	O	O	O
.	.	O	O	O	O

MAIN	main	O	O	O	O
RESULTS	results	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
was	was	O	O	O	O
significantly	significantly	O	O	O	O
lower	lower	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
group	group	O	O	O	O
(	(	O	O	O	O
6.7	6.7	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
than	than	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
placebo	placebo	O	O	O	O
group	group	O	O	O	O
(	(	O	O	O	O
70	70	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

None	none	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
experienced	experienced	O	O	O	O
sedation	sedation	O	O	O	O
,	,	O	O	O	O
apnea	apnea	O	DISEASE	OTHERS	I
,	,	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
pruritus	pruritus	O	DISEASE	OTHERS	I
after	after	O	O	O	O
injection	injection	O	O	O	O
of	of	O	O	O	O
both	both	O	O	O	O
drugs	drugs	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
placebo	placebo	O	O	O	O
group	group	O	O	O	O
,	,	O	O	O	O
male	male	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
significantly	significantly	O	O	O	O
increased	increased	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
after	after	O	O	O	O
etomidate	etomidate	O	O	OTHERS	I
administration	administration	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
Pretreatment	pretreatment	O	O	O	O
with	with	O	O	O	O
remifentanil	remifentanil	O	O	OTHERS	I
1	1	O	O	O	O
microg/kg	microg/kg	O	O	O	O
reduced	reduced	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
after	after	O	O	O	O
etomidate	etomidate	O	O	OTHERS	I
induction	induction	O	O	O	O
without	without	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
sedation	sedation	O	O	O	O
,	,	O	O	O	O
apnea	apnea	O	DISEASE	OTHERS	I
,	,	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
pruritus	pruritus	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Men	men	O	O	O	O
experience	experience	O	O	O	O
increased	increased	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
than	than	O	O	O	O
women	women	O	O	O	O
after	after	O	O	O	O
etomidate	etomidate	O	O	OTHERS	I
administration	administration	O	O	O	O
.	.	O	O	O	O

